The United Kingdom and the United States have forged a key commercial pact that will maintain no duties on UK medicine shipments being sold in the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to boost funding on pharmaceuticals through the public health system. This move ensures that duties on these vital exports will be held at zero for a timeframe of the next three years.
This agreement follows earlier warnings to hike tariffs on branded drug imports, with potential rates floated reaching double the cost.
"This deal with the UK bolsters the worldwide climate for innovative medicines and establishes much-needed equity to transatlantic medicine commerce," a statement declared.
Trade Impact
Pharmaceuticals represent one of the the United Kingdom's largest exports to the America, which is by far the primary buyer for major UK drugmakers.
Export figures show that in the 12 months prior to September, the UK exported drugs totaling £11.1bn to the US. This amount made up a significant portion of total UK exports in that timeframe.
"This guarantee secures jobs, increases funding and facilitates the UK to become a global hub for life sciences," the Business and Trade Secretary remarked.
Specific NHS Changes
The agreement involves several key pledges from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to increase overall NHS spending on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to control costs will be restricted at fifteen percent. Previously, rebates were more than 20%.
Recent Tensions
The deal follows a ongoing tension between the pharmaceutical industry and the ministers over medicine costs and regulatory access.
This friction were exacerbated by assertions that US customers were charged significantly more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been halted or cancelled, while major investments have been announced toward American operations.
The Science Minister publicly accepted that the NHS needed to spend more on drugs, noting that its expenditure on drugs had shrunk as a proportion of its resources over the last ten years.
